1-2 of 2
Rolf Stahel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Available to Purchase
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 64–72.
https://doi.org/10.1158/1078-0432.CCR-18-1590
Published: 03 January 2019
View articletitled, Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Open the PDF for Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers in another window
Includes: Supplementary data
Journal Articles

Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program

Available to Purchase
Martin Filipits, Vincent Haddad, Katharina Schmid, Anh Huynh, Ariane Dunant, Fabrice André, Elisabeth Brambilla, Rolf Stahel, Jean-Pierre Pignon, Jean-Charles Soria, Helmut H. Popper, Thierry Le Chevalier, Robert Pirker
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3892–3898.
https://doi.org/10.1158/1078-0432.CCR-06-2446
Published: 02 July 2007
View articletitled, Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program
Open the PDF for Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program in another window